NCT07007637Phase 3Enrolling by invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Study sponsor: MoonLake Immunotherapeutics AG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06-13Estimated
Enrollment · participants835Estimated
Source updated2026-06-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview